Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes
Key Highlights
- ➤KO-7246 restored glycemic control and increased β-cell mass in Type 1 diabetes models
- ➤KO-7246 produced a 3.4-fold increase in β-cell mass in Type 2 diabetes mice
- ➤KO-7246 enhanced activity in combination with semaglutide without hypoglycemia
- ➤KO-7246 is advancing through IND-enabling development toward initial clinical evaluation
- ➤Kura Oncology (KURA) and Caspian will host an investor webcast October 13, 2026
Expert Statements
Francis Burrows, Chief Scientific Officer of Kura Oncology
“Menin is a compelling target in diabetes because multiple lines of evidence, from human physiology and genetics to pharmacologic studies, point to its role in regulating β-cell mass.”
Francis Burrows, Chief Scientific Officer of Kura Oncology
“KO-7246 gives us a potent, selective way to test whether menin inhibition can harness this biology to restore endogenous insulin-producing capacity in both Type 1 and Type 2 diabetes.”
Francis Burrows, Chief Scientific Officer of Kura Oncology
“Its potency and selectivity as a menin inhibitor, as well as its activity in a range of diabetes preclinical models, distinguish KO-7246 from earlier approaches and support its potential to become a best-in-class menin inhibitor for diabetes.”
Robert Spencer, President and Chief Operating Officer of Caspian Therapeutics
“We believe KO-7246 has one of the most comprehensive preclinical profiles reported for a menin inhibitor being developed for diabetes.”
Robert Spencer, President and Chief Operating Officer of Caspian Therapeutics
“It combines bona fide menin pharmacology with durable β-cell regeneration, activity in both Type 1 and Type 2 diabetes models, and potent and selective effects on β cells in human islets.”
Robert Spencer, President and Chief Operating Officer of Caspian Therapeutics
“We believe these data provide a strong foundation for KO-7246 to become a best-in-class menin inhibitor and for Caspian to lead the development of menin-directed therapies for diabetes and other cardiometabolic diseases.”
– KO-7246 regenerated functional β-cell mass and produced durable glycemic control in Type 1 and Type 2 diabetes models –
– KO-7246 has potential to complement existing diabetes therapies with a novel mechanism of action, evidenced by post-treatment durability and combination benefit with semaglutide –
Get started
Create a free account to read the full story.